Top

Published in:

01-04-2013 | Review

Searching the optimal PTH target range in children undergoing peritoneal dialysis: New insights from international cohort studies

Authors: Dieter Haffner, Franz Schaefer

Published in: Pediatric Nephrology | Issue 4/2013

Abstract

The treatment of the mineral and bone disorder associated with chronic kidney disease (CKD-MBD) remains a major challenge in pediatric patients. The principal aims of therapeutic measures are not only to prevent the debilitating skeletal complications and to achieve normal growth but also to preserve long-term cardiovascular health. Serum parathyroid hormone (PTH) levels are used as a surrogate parameter of bone turnover. Whereas it is generally accepted that serum calcium and phosphate levels should be kept within the range for age, current pediatric consensus guidelines differ markedly with respect to the optimal PTH target range and operate on a limited evidence base. Recently, the International Pediatric Dialysis Network (IPPN) established a global registry collecting detailed clinical and biochemical information, including data relevant to CKD-MBD in children on chronic peritoneal dialysis (PD). This review highlights the current evidence basis regarding the optimal PTH target range in pediatric CKD patients, and re-assesses the current guidelines in view of the outcome data collected by the IPPN registry. Based on a comprehensive evaluation of CKD-MBD outcome measures in this global patient cohort, a PTH target range of 1.7–3 times the upper limit of normal (i.e. 100–200 pg/ml) appears reasonable in children undergoing chronic PD.

Wesseling-Perry K, Salusky IB (2009) Chronic kidney disease mineral and bone disorder. In: Avner D-D, Harmon W-E, Niaudet P, Yoshikawa N (eds) Pediatric Nephrology, 6th edn. Springer, New York, pp S1755–S1783CrossRef

Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105PubMedCrossRef

Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 18:1478–1483CrossRef

Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Kidney disease: improving global outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945–1953PubMedCrossRef

http://www.kidney.org/professionals/kdoqi/guidelines_pedbone/index.htm

Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schröder C, Zurowska A, Ekim M, European Paediatric Dialysis Working Group (EPDWG) (2006) Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21:151–159PubMedCrossRef

Rees I (2008) What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what ist he evidence? Pediatr Nephrol 23:179–184PubMedCrossRef

Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG (1994) Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253–258PubMedCrossRef

Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205–211PubMedCrossRef

10.

Schmitt CP, Mehls O (2011) Mineral and bone disorders in children with chronic kidney disease. Nat Rev Nephrol 7:624–634PubMedCrossRef

11.

Schlüter KD, Piper HM (1992) Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol 263:H1739–H1746PubMed

12.

Amann K, Ritz E, Wiest G, Klaus G, Mall G (1994) A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4:1814–1819PubMed

13.

Wesseling K, Bakkaloglu S, Salusky I (2008) Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol 23:195–207PubMedCrossRef

14.

Foundation NK (2005) K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46(4 Suppl 1):S1–S121

15.

Mathias R, Salusky I, Harman W, Paredes A, Emans J, Segre G, Goodman W (1993) Renal bone disease in pediatric and young adult patients on hemodialysis in a children’s hospital. J Am Soc Nephrol 12:1938–1946

16.

Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, Sahney S, Gales B, Jüppner H, Salusky IB (2012) Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 7:146–152PubMedCrossRef

17.

Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, Gokal R, Hoyland JA (2000) Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 58:1440–1449PubMedCrossRef

18.

Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M (2005) Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant 20:1904–1911PubMedCrossRef

19.

Wesseling-Perry K, Salusky IR (2012) Diagnosis and management of renal osteodystrophy in children. In: Warady BA, Schaefer F, Alexander SR (eds) Pediatric Dialysis, 2nd edn. Springer, New York, pp S483–S503CrossRef

20.

Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A (2000) A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753–761PubMed

21.

Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D’Amour P (2001) Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142:1386–1392PubMedCrossRef

22.

Ziólkowska H, Pańiczyk-Tomaszewska M, Debiński A, Polowiec Z, Sawicki A, Sieniawska M (2000) Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 89:666–671PubMedCrossRef

23.

Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, Salusky IB (2010) Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol 5:1860–1865PubMedCrossRef

24.

Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ (2012) PTH–A Particularly Tricky Hormone: Why Measure It at All in Kidney Patients? Clin J Am Soc Nephrol. doi:10.2215/CJN.09580911

25.

Cantor T, Yang Z, Caraiani N (2006) Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 52:1771–1776PubMedCrossRef

26.

Souberbielle JC, Boutten A, Carlier MC (2006) Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 70:345–350PubMedCrossRef

27.

Souberbielle JC, Roth H, Fouque DP (2010) Parathyroid hormone measurement in CKD. Kidney Int 77:93–100PubMedCrossRef

28.

Schmitt CP, Ardissino G, Testa S, Claris-Appiani A, Mehls O (2003) Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol 18:440–444PubMed

29.

Waller S, Shroff R, Freemont AJ, Rees L (2008) Bone histomorphometry in children prior to commencing renal replacement therapy. Pediatr Nephrol 23:1523–1529PubMedCrossRef

30.

Cansick J, Waller S, Ridout D, Rees L (2007) Growth in prepubertal children on long-term dialysis. Pediatr Nephrol 22:1349–1354PubMedCrossRef

31.

Haffner D, Fischer DC (2012) Growth and Puberty. In: Warady BA, Schaefer F, Alexander SR (eds) Pediatric Dialysis, 2nd edn. Springer, New York, pp S453–S482CrossRef

32.

Briese S, Wiesner S, Will JC, Lembcke A, Opgen-Rhein B, Nissel R, Wernecke KD, Andreae J, Haffner D, Querfeld U (2006) Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. Nephrol Dial Transplant 21:1906–1914PubMedCrossRef

33.

Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2005) Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. J Am Soc Nephrol 16:2796–2803PubMedCrossRef

34.

Litwin M, Wühl E, Jourdan C, Trelewicz J, Niemirska A, Fahr K, Jobs K, Grenda R, Wawer ZT, Rajszys P, Tröger J, Mehls O, Schaefer F (2005) Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 16:1494–1500PubMedCrossRef

35.

Civilibal M, Caliskan S, Adaletli I, Oflaz H, Sever L, Candan C, Canpolat N, Kasapcopur O, Kuruoglu S, Arisoy N (2006) Coronary artery calcifications in children with end-stage renal disease. Pediatr Nephrol 21:1426–1433PubMedCrossRef

36.

Lumpaopong A, Mathew AV, John E, Jelnin V, Benedetti E, Testa G, Oberholzer J, Sankary H, Ruiz C (2007) Early coronary calcification in children and young adults with end-stage renal disease. Transplant Proc 39:37–39PubMedCrossRef

37.

Shroff RC, Donald AE, Hiorns MP, Watson A, Feather S, Milford D, Ellins EA, Storry C, Ridout D, Deanfield J, Rees L (2007) Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 18:2996–3003PubMedCrossRef

38.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113:S1–S130

39.

Borzych D, Rees L, Ha IS, Chua A, Valles PG, Lipka M, Zambrano P, Ahlenstiel T, Bakkaloglu SA, Spizzirri AP, Lopez L, Ozaltin F, Printza N, Hari P, Klaus G, Bak M, Vogel A, Ariceta G, Yap HK, Warady BA, Schaefer F, International Pediatric PD Network (IPPN) (2010) The bone and mineral disorder of children undergoing chronic peritoneal dialysis. Kidney Int 78:1295–1304PubMedCrossRef

40.

Bakkaloglu SA, Borzych D, Soo Ha I, Serdaroglu E, Büscher R, Salas P, Patel H, Drozdz D, Vondrak K, Watanabe A, Villagra J, Yavascan O, Valenzuela M, Gipson D, Ng KH, Warady BA, Schaefer F, International Pediatric Peritoneal Dialysis Network (2011) Cardiac geometry in children receiving chronic peritoneal dialysis: Findings from the International Pediatric Peritoneal Dialysis Network (IPPN) registry. Clin J Am Soc Nephrol 6:1926–1933PubMedCrossRef

41.

Saleh FN, Schirmer H, Sundsfjord J, Jorde R (2003) Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 24:2054–2060PubMedCrossRef

42.

Iqbal A, Jorde R, Lunde P, Sundsfjord J, Rasmussen K (2006) Left ventricular dysfunction in subjects with mild secondary hyperparathyroidism detected with pulsed wave tissue Doppler echocardiography. Cardiology 105:1–8PubMedCrossRef

43.

Borzych D, Bilginer Y, Warady BA, Schaefer F and Coinvestigator. ₁Center for Pediatric Medicine, Heidelberg, Germany; ₂Hacettepe University, Ankara, Turkey; ₃Children`s Mercy Hospital, Kansas City, MO, United States (2010) Global outcomes of anemia management in dialyzed children: Results from the IPPN Registry. Pediatr Nephrol 25:1938 (abstract)

44.

Stralen KJ, Krischock L, Schaefer F, Verrina E, Groothoff JW, Evans J, Heaf J, Ivanov D, Kostic M, Maringhini S, Podracká L, Printza N, Pundziene B, Reusz GS, Vondrak K, Jager KJ, Tizard EJ (2012) Prevalence and Predictors of Sub-target Hb level in Children on Dialysis. Nephrol Dial Transplant. doi:10.1093/ndt/gfs178

45.

Belsha CW, Berry PL (1998) Effect of hyperparathyroidism on response to erythropoietin in children on dialysis. Pediatr Nephrol 12:298–303PubMedCrossRef

46.

Drüeke TB, Eckardt KU (2002) Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 17(Suppl 5):28–31PubMedCrossRef

47.

Borzych D, Serdaroglu E, Ha IS, Rees L, Azocar M, Büscher A, Vogel A, Kim YH, Warady BA, Schaefer F (2011) Causes of death and predictors of survival in pediatric PD: Insights from the International Pediatric PD Network (IPPN) registry. Pediatr Nephrol 26:1583 (abstract)

48.

Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J, Wahl P, Lundquist A, Epstein M, Smith K, Contreras G, Ortega L, Lenz O, Briones P, Egbert P, Ikizler TA, Jueppner H, Wolf M (2011) Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 6:2688–2695PubMedCrossRef

49.

Gardham C, Stevens PE, Delaney MP, LeRoux M, Coleman A, Lamb EJ (2010) Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 5:1261–1267PubMedCrossRef

Title: Searching the optimal PTH target range in children undergoing peritoneal dialysis: New insights from international cohort studies
Authors: Dieter Haffner
Franz Schaefer
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 4/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-012-2270-1

At a glance: The STEP trials

Springer Medicine

Searching the optimal PTH target range in children undergoing peritoneal dialysis: New insights from international cohort studies

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Using height association studies to gain insights into human idiopathic short and syndromic stature phenotypes

Ocular involvement in a child with medullary nephrocalcinosis: Answers

Ghrelin and cachexia in chronic kidney disease

Cystatin C in children on chronic hemodialysis

Risk factors for urinary stones in healthy schoolchildren with and without a family history of nephrolithiasis

Prediction of steroid-sparing agent use in childhood idiopathic nephrotic syndrome